vimarsana.com

Page 40 - சீரம் நிறுவனம் ஆஃப் இந்தியா லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Coronavirus: India Has Plenty of Covid Shots, Not Enough Willing To Take Them

As of Monday, India distributed about 2 million shots nationwide. Highlights India may fall far short of its target of inoculating 300 million people India says it can produce 500 million shots per month for export Most of the world is struggling to secure enough vaccines to inoculate their populations. India has the opposite problem: Plenty of shots, but a shortage of people willing to take them. As India rolls out one of the world s biggest inoculation programs, some health-care and other frontline workers are hesitating because of safety concerns over a vaccine that has yet to complete phase III trials. As of Monday, only about 56% of people eligible to get the shot have stepped forward in a nation with the world s second-worst Covid-19 outbreak.

India s unusual Covid vaccine problem: Shots in abundance, but few takers

AstraZeneca to Test If Longer Wait Between Vaccine Doses Works Better

AstraZeneca to Test If Longer Wait Between Vaccine Doses Works Better Bloomberg 1/27/2021 Suzi Ring © Bloomberg Vials of Covishield, the local name for the Covid-19 vaccine developed by AstraZeneca Plc. and the University of Oxford, move along a conveyor on the production line at the Serum Institute of India Ltd. Hadaspar plant in Pune, Maharashtra, India, on Friday, Jan. 22, 2021. (Bloomberg) AstraZeneca Plc plans to conduct a global study on the optimal interval between the two doses of its Covid-19 vaccine as questions linger over how to elicit the best protection for the greatest number of people. Popular Searches The new trial will investigate a two-month gap between shots to determine whether it can provide better efficacy, Chief Executive Pascal Soriot told a group of European newspapers Tuesday. The U.K. approved the vaccine, developed with the University of Oxford, last month with a 4- to 12-week dosing interval.

Escalating AstraZeneca Spat Highlights EU Vaccine Fiasco

Escalating AstraZeneca Spat Highlights EU Vaccine Fiasco Bloomberg 1/26/2021 Nikos Chrysoloras and Arne Delfs © Bloomberg A vaccine cold storage area at the Serum Institute of India Ltd. Hadaspar plant in Pune, India. (Bloomberg) The European Union’s standoff with AstraZeneca Plc over delayed vaccine deliveries widened, with Germany taking aim at U.S. export restrictions and signaling its backing for similar curbs. Popular Searches German Chancellor Angela Merkel hinted at potential retaliation against the U.S. after her government called for a limit on exports of vaccines out of the bloc, adding to signs of ever more brutal competition for the life-saving shots.

Old notes of ₹100, 10 and 5 to be demonetised? What the govt has to say

Old notes of ₹100, 10 and 5 to be demonetised? What the govt has to say All banknotes in the denomination of ₹ 100 issued by the RBI in the earlier series will continue to be legal tender, RBI had said. (Reuters)Premium Share Via Read Full Story Several reports are doing rounds that the old banknotes of ₹100, 10 and 5 would be demonetised by March-April. The government s fact-checking unit has termed has debunked the report and said the central bank has not made any such announcements. The Press Information Bureau (PIB) conducted a fact check and termed the report as FAKE. “It is being claimed that hundred, ten and 5 rupee notes will no longer be legal tender from March 21, as per the information given by RBI. This claim is false , the PIB tweeted.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.